![](/img/cover-not-exists.png)
Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer’
Rowland, Andrew, Dias, Mafalda M, Wiese, Michael D, Kichenadasse, Ganessan, McKinnon, Ross A, Karapetis, Christos S, Sorich, Michael JLanguage:
english
Journal:
British Journal of Cancer
DOI:
10.1038/bjc.2015.325
Date:
September, 2015
File:
PDF, 110 KB
english, 2015